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Abstract
Purpose Treatment with cetuximab is accompanied by
the development of an acneiform follicular skin exanthema
in more than 80 % of patients. Severe exanthema (grade
III/IV) develops in about 9–19 % of patients with the
necessity of cetuximab dose reduction or cessation.
Methods The study presented was a retrospective analysis
of 50 gastrointestinal cancer patients treated with cetux-
imab in combination with either FOLFIRI or FOLFOX.
One cohort of 15 patients received an in-house reactive
skin protocol upon development of an exanthema. A sec-
ond cohort of 15 patients received a skin prophylaxis
starting with the first dose of cetuximab before clinical
signs of toxicity. A third historic group of 20 patients had
received no skin prophylaxis or reactive treatment.
Results 19/20 patients of the historic group developed a
skin exanthema. Grade III/IV exanthema was observed six
times. Forty percent discontinued cetuximab therapy. The
average time to exanthema onset was 14.7 days. Applying
the reactive skin protocol after the first occurrence of an
exanthema, the exanthema was downgraded as follows: No
patients developed grade IV exanthema, and two patients
developed a grade II/III exanthema. In the majority of
cases, the reactive skin protocol controlled the exanthema
(grade 0–I). No dose reductions in cetuximab were nec-
essary. Applying the prophylactic skin protocol starting at
the beginning of cetuximab application was not superior to
the reactive skin protocol.
Conclusions Cetuximab-induced skin exanthema can be
coped with a reactive protocol equally effective as com-
pared to a prophylactic skin treatment. A prospective study
with higher patient numbers is planned.
Keywords Skin  Rash  Exanthema  EGFR 
Cetuximab  Therapy reactive
Introduction
The inhibition of growth factor signaling pathways has
proven to be an effective therapeutic option in a quite
variety of tumor entities. Epidermal growth factor receptor
(EGFR) inhibitors, for instance, are used in the treatment of
colorectal cancer, head and neck cancer, non-small cell
lung cancer, and pancreatic cancer among other malig-
nancies (Ciuleanu et al. 2012; Saltz et al. 2004; Luedke
et al. 2012; Busam et al. 2001) and are in general well
tolerated. However, EGFR inhibitors, such as cetuximab,
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have the potential to induce a skin exanthema of follicular
origin that occurs in the majority of patients (Ciuleanu
et al. 2012). This exanthema has an acneiform appearance
(Busam et al. 2001) and can present itself as maculae,
papulae, or small pustulae occurring on the face, de´collete´,
or back. In addition, it may be accompanied by symptoms
such as burning or itching.
Usually, it takes up to 2 or 3 weeks after the first intake
of the EGFR inhibitor until the first signs of exanthema.
Most patients only suffer from mild exanthemas (grade I
and II). Nevertheless, about a fifth of the patients will
experience severe exanthemas (grade III or IV). More
severe or persistent exanthemas are eventually seen when
EGFR antibodies are administered (Busam et al. 2001). By
the occurrence of a severe exanthema, pause or dose
reduction of the EGFR inhibitor can be considered. Dis-
continuation is necessary in approximately 10 % of
patients (Busam et al. 2001). However, as patients are told
that the development and intensity of an exanthema are
rather associated with a better prognosis, the withdrawing
of EGFR inhibitors from cancer therapy can be perturbing
for the respective patients (Stintzing et al. 2012). Male
gender and age below 70 years are considered as risk
factors for the development of severe exanthemas (La-
couture et al. 2011).
Bothersome for the concerned patients, there is no
standardized therapy for the therapy of skin toxicities. They
are mostly coped with known strategies established for the
therapy of acne. In the recent past, first randomized trials
analyzed the prophylaxis and therapy of cetuximab-
induced skin exanthemas (Lacouture et al. 2011; Scope
et al. 2007; Jatoi et al. 2008).
Less severe and less symptomatic skin exanthemas were
reported by a prophylactic intake of oral minocycline
(Scope et al. 2007). However, this effect was only tem-
porary and vanished in the long run. Similar results were
reported by Jatoi et al. They analyzed the prophylactic
effect of an oral tetracycline application on the develop-
ment of skin exanthemas grade CII. Efficacy was
observed during the first weeks but not in a long-term
setting (Scope et al. 2007). The mentioned antibiotics are
commonly used for the treatment of acne. The clinical
similarity between classical acne and an EGFR inhibitor-
induced skin exanthema suggests that this medication
might be successfully used for prevention or treatment of
drug-induced exanthemas (Gammon et al. 1986; Meyna-
dier and Alirezai 1998). However, the anti-inflammatory
effects of tetra-/doxy-/and minocycline might also support
exanthema palliation (Meynadier and Alirezai 1998; Fujita
et al. 2007).
Another randomized phase II study analyzed the effect
of a prophylactic versus reactive therapy during second-
line panitumumab therapy in colorectal cancer (Lacouture
et al. 2010). The prophylactic therapy including lotion, oral
doxycycline, topical hydrocortisone (1 %), and sun block
resulted in a significant reduction in skin exanthemas grade
CII. However, weak points in this study were the topical
administration of topical cortisone in the prophylactic arm
and the undefined reactive treatment regimen.
In view of these data, we retrospectively compared three
patient populations who had received cetuximab therapy
with either no standard skin treatment (historic group), or
an in-house reactive skin protocol that was based on the
therapeutic options of classical acne and treatment rec-
ommendations of the cetuximab manufacturer, or a pro-
phylactic treatment with cleansing syndet, topical
metronidazole ointment, and doxycycline 100 mg twice
per day. We were able to perform this retrospective anal-
ysis, as we had established a reactive skin protocol and a
prophylactic skin protocol several years ago and docu-
mented all skin toxicities according to National Cancer
Institute’s Common Terminology Criteria for Adverse
Events version 3.0 (NCI CTCAE v3.0) and digital pho-
tography. The decision whether a patient received reactive
therapy or a prophylactic therapy was left to the patient.
Methods
Patients
Due to a lack of standardized guidelines, we stuck to an in-
house reactive skin protocol and a prophylactic skin pro-
tocol derived from the common acne therapy, which was
offered to all patients treated with cetuximab. The skin
protocols were offered for the first time to a patient in April
2008. We retrospectively analyzed all patients receiving
the reactive skin protocol under cetuximab-based chemo-
therapy starting from April 2008. However, we did not
include the patient population reported earlier.
All adverse events were routinely documented on a
weekly basis as per the NCI CTCAE v3.0 criteria. The
evaluation entailed physical examination: a weekly
assessment of patient performance status and weight; and
an assessment of adverse events, including gastrointestinal
toxicity and exanthema development. Skin toxicities were
documented weekly by digital photography (Fig. 1).
Reactive skin protocol
The reactive skin protocol was established as follows:
grade I exanthema; topical cleansing syndet [Dermo-
was]; and topical metronidazole cream (7.5 %) on
affected skin areas [Rosiced]. Grade II exanthema: See
grade I treatment plus oral minocycline 50 mg twice
daily. Grade III exanthema: See grade II treatment plus
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topical corticoid prednicarbat cream (0.25 %) on affected
skin areas [Dermatop] (Fig. 2). As soon as a grade III
had improved to grade BII, application of topical corticoid
was ceased.
It was specified that patients were to be withdrawn from
minocycline in the event of Cgrade II, nausea, and/or
vomiting. The latter was characterized by two to five epi-
sodes of nausea/vomiting within 24 h.
Prophylactic skin protocol
The prophylactic skin treatment protocol consisted of the
application of a topical cleansing syndet [Dermowas], a
topical 7.5 % metronidazole ointment [Rosiced], and
doxycycline 100 mg (p.o.) twice per day (exanthema[II;
?topical corticoid prednicarbat cream (0.25 %) [Derma-
top]). In case of rash [grade II, the skin treatment was
identically performed as in the reactive skin protocol.
Statistical analysis
Our data were explored in a retrospective descriptive set-
ting using t test and v2-test.
Results
Patients
A total number of 50 patients were treated with cetuximab.
Twenty patients of the historic cohort did not receive a
standard skin treatment. Fifteen patients of the second
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Fig. 1 TKI-associated acneiform exanthema. TKI associated acneiform exanthema is classified according NCI CTCAE3.0


































Fig. 2 Prophylactic treatment
regimen applied to group C and
reactive treatment regimen
applied to group B
J Cancer Res Clin Oncol (2013) 139:1667–1672 1669
123
cohort were treated according to our in-house reactive skin
protocol starting in June 2008. Upon retrospective evalu-
ation, all patients had received treatment under this pro-
tocol for a minimum of 12 weeks. In the third cohort, 15
patients received a prophylactic skin treatment consisting
of a topical cleansing syndet [Dermowas], a topical
metronidazole ointment [Rosiced], and doxycycline
100 mg (p.o.) twice per day. None of the patients had a
history of acne. The retrospective analysis was conducted
according to the requirements of the local ethics committee
and was performed with the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amendments.
All patients suffered from a gastrointestinal adenocar-
cinoma stage UICC IV. All patients had a history of che-
motherapy consisting of a standard initial cetuximab dose
of 400 mg/qm and thereafter 250 mg/qm weekly combined
with either irinotecan or platinum-based chemotherapy.
None of the patient received radiation.
Exanthema
During the first 12 weeks of therapy with cetuximab, 19/20
(95 %) patients in the historic cohort (group A) developed
a skin exanthema: One patient (5 %) developed a grade IV
exanthema, 5 patients (25 %) experienced a grade III, and
13 patients (65 %) a grade II exanthema. Only one patient
did not show clinical signs of exanthema (Fig. 3). Forty
percent discontinued cetuximab therapy due to side effects
(Fig. 4). Time to onset ranged from 1 to 4 weeks, and
average time to onset was 14.7 days (Fig. 5).
In the second cohort receiving a reactive skin protocol
(group B), all patients developed a skin exanthema (15/15;
100 %) within the first three months of cetuximab appli-
cation: Two patients (13 %) developed a grade III exan-
thema, eight patients (53 %) experienced a grade II
exanthema, and five patients (33 %) a grade I exanthema
(Fig. 3). Time to onset ranged from 1 to 4 weeks with an
average time to onset of 13.2 days (Fig. 4). No patient had
to discontinue cetuximab therapy (Fig. 5). No skin
protocol-associated adverse events occurred. No patient
terminated the in-house reactive skin protocol.
During the first 12 weeks of therapy with cetuximab in
the third cohort receiving a prophylactic regimen (group
C), all patients developed a skin exanthema (15/15;
100 %): One patient (7 %) developed a grade IV exan-
thema, and one patient (7 %) developed a grade III
exanthema, while 9 patients (60 %) experienced a grade II
exanthema and four patients (27 %) a grade I exanthema
(Fig. 3). Time to onset ranged from 1 to 4 weeks, and
average time to onset was 13.9 days (Fig. 5). One patient
had to discontinue cetuximab therapy (Fig. 4).
A comparison of maximum exanthema (grade 0, I versus
grade II, III, IV) in the three cohorts showed a significant
difference between the historic cohort and the ‘‘reactive
treatment’’ cohort (p = 0.027). Similar results exist between
‘‘historic’’ cohort group A and the ‘‘prophylactic treatment’’
cohort (group C; p = 0.069). However, there exists no
significant difference between group B and C (p = 0.69).
Fig. 3 Occurrence of symptoms. Occurrence of maximum acneiform
exanthema in the historic cohort A compared to the ‘‘reactive
treatment’’ cohort B and ‘‘prophylactic treatment’’ group C







Fig. 4 Frequency of therapy interruption. The ‘‘historic’’ cohort
shows a frequency of 40 % therapy interruption compared to 0 % in
cohort B and 7 % in cohort C
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Fig. 5 Time to occurrence of Cgrade II exanthema. No significant
difference between the three cohorts exits in terms of time to first
exanthema occurrence
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Discussion
To our knowledge, this is the first study comparing a
reactive skin protocol with a prophylactic skin therapy in
cetuximab-treated patients. Although two-third of the
patients in the ‘‘reactive treatment’’ cohort developed a
symptomatic grade CII exanthema shortly after initiation
of a cetuximab therapy, all patients were stabilized and had
either no or only a very light grade I exanthema after
initiation of the reactive skin therapy. Note worthy is that
the ‘‘prophylactic treatment’’ cohort showed equal effec-
tive but no superior results in preventing toxicity grade CII.
Thus, a prophylactic use of topical skin and oral doxycy-
cline treatment does not seem to improve efficacy but
might be easier to handle in everyday practice and might
also improve compliance. However, patients will have a
higher intake of medication without superior results. As
also presented earlier by our group, the use of the simple
reactive skin protocol presented herein can prevent the
exacerbation of a cetuximab-induced follicular acneiform
exanthema. The application of this protocol prevented a
cetuximab dose reduction or cessation in patients at risk.
Protocol-induced adverse effects were not observed.
Only few reports about the therapeutic options of anti-
EGFR skin exanthemas are published. In most cases, pro-
phylactic approaches were chosen. The prophylactic
application of oral antibiotics (tetracycline or minocycline)
alone was effective for the early phase of the exanthema
during the first month of anti-EGFR treatment (Scope et al.
2007; Jatoi et al. 2008).
A decrease in the incidence of grade CII exanthemas
was noted. In addition, tetracycline and minocycyline-
treated patients reported other favorable symptomatic
effects, including less itching, less burning and stinging,
and less skin irritation compared to patients treated with
placebo. However, these positive effects vanished after
longer application. Similarly, topical usage of pimecroli-
mus, a calcineurin inhibitor, did not result in symptomatic
relief or improvement of the severity of the cetuximab-
induced exanthema (Scope et al. 2009). As anti-EGFR
strategies, such as cetuximab, are part of a long-term
cancer therapy, isolated usage of oral antibiotics seems to
be an insufficient approach and has to be seen critically.
The STEPP study combined oral doxycycline with topical
hydrocortisone (1 %) in a prophylactic setting (Lacouture
et al. 2010). This approach resulted in a dramatic reduction in
more severe exanthema and prolongation of time to onset of
grade CII exanthemas. However, this study has been often
criticized, as all patients randomized in the prophylaxis arm
had been exposed to topical hydrocortisone.
In our reactive skin protocol setting, only 13 % of
patients, namely those who developed a grade III exan-
thema, actually needed topical corticoid for a short period
of time (maximum 3 weeks). Thus, it can be hypothesized
that many patients participating in the STEPP study might
have been exposed to hydrocortisone, unnecessarily.
The relevant limitation of our study is its retrospective
setting and the number of patients treated. Thus, it is dif-
ficult to derive any validated clinical recommendations
resulting from this report. A prospective study will be
necessary in order to confirm our observations. Thus, there
is a compelling need to continue and conduct research on
how best to prevent and palliate exanthemas that occur
from anti-EGFR therapy.
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